About
Technology
Issues
FAQ
Search
Profile
Top Authors
Prolific Authors
Top Journals
Main Disciplines
Main Topics
Most Cited Articles
Scientometrics
Avg Impact Factor
★★
Articles
★★★
Articles
Citing Bodies
Top Citing Authors
Top Citing Institutions
Top Citing Schools
Top Citing Journals
Top Citing Disciplines
exaly
›
Schools
›
Global Medical Affairs
›
Top Articles
Global Medical Affairs
33
(top 2%)
papers
1.1K
(top 2%)
citations
14
(top 2%)
h
-index
25
(top 2%)
g
-index
36
all documents
1.1K
doc citations
519
citing journals
26
times ranked
Top Articles
#
Title
Journal
Year
Citations
1
XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation
European Heart Journal
2016
383
2
GIDEON
(Global Investigation of therapeutic
DE
cisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis
International Journal of Clinical Practice
2014
215
3
First interim analysis of the GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) non-interventional study
International Journal of Clinical Practice
2012
102
4
Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial
Lancet Respiratory Medicine,the
2021
85
5
Regional differences in sorafenib‐treated patients with hepatocellular carcinoma:
GIDEON
observational study
Liver International
2016
44
6
Interferon-beta-1b-induced short- and long-term signatures of treatment activity in multiple sclerosis
Pharmacogenomics Journal
2013
36
7
Perfusion CT in acute stroke: prediction of vessel recanalization and clinical outcome in intravenous thrombolytic therapy
European Radiology
2007
35
8
REVEAL risk score in patients with chronic thromboembolic pulmonary hypertension receiving riociguat
Journal of Heart and Lung Transplantation
2018
29
9
REVEAL risk scores applied to riociguat-treated patients in PATENT-2: Impact of changes in risk score on survival
Journal of Heart and Lung Transplantation
2018
29
10
Effects of Rivaroxaban on Biomarkers of Coagulation and Inflammation: A Post Hoc Analysis of the X-VeRT Trial
TH Open
2020
29
11
Treatment of endometriosis in different ethnic populations: a meta-analysis of two clinical trials
BMC Women's Health
2012
25
12
Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study
BMC Pulmonary Medicine
2017
23
13
Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome
Multiple Sclerosis Journal
2014
19
14
Safety and efficacy of sorafenib therapy in patients with hepatocellular carcinoma: final outcome from the Chinese patient subset of the GIDEON study
Oncotarget
2016
18
15
The Three-Decade Long Journey in Heart Failure Drug Development
Handbook of Experimental Pharmacology
2016
12
16
Left atrial thrombus resolution in non-valvular atrial fibrillation or flutter: biomarker substudy results from a prospective study with rivaroxaban (X-TRA)
Annals of Medicine
2018
12
17
Effect of riociguat on right ventricular function in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
Journal of Heart and Lung Transplantation
2021
9
18
Type I Interferon Receptor Expression in Human Pancreatic and Periampullary Cancer Tissue
Pancreas
2015
7
19
Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
European Respiratory Review
2022
6
20
Application of the REVEAL risk score calculator 2.0 in the PATENT study
International Journal of Cardiology
2021
5
21
Sorafenib treatment by Child–Pugh score in Latin American patients with hepatocellular carcinoma
Future Oncology
2020
4
22
Change in REVEAL Lite 2 risk score predicts outcomes in patients with pulmonary arterial hypertension in the PATENT study
Journal of Heart and Lung Transplantation
2022
4
23
Aorto‐Peripheral MDCT Angiography: Implications for Contrast Medium Delivery
Imaging Decisions (Berlin, Germany)
2008
3
24
Patient-reported outcomes associated with switching to rivaroxaban for the treatment of venous thromboembolism (VTE) in patients with active cancer
Annals of Oncology
2019
3
25
Switching from PDE5i to Riociguat in the RESPITE Study: Effect on Right Heart Function
Journal of Heart and Lung Transplantation
2018
2
26
Validation of REVEAL Risk Score Calculator 2.0 in Patients with CTEPH in the Phase III CHEST Study
Journal of Heart and Lung Transplantation
2020
2
27
400P Impact of regorafenib dose optimization on comparative outcomes in the treatment of relapsed/refractory metastatic colorectal cancer (mCRC)
Annals of Oncology
2022
2
28
Application of the REVEAL risk score calculator 2.0 in the CHEST study
Respiratory Medicine
2022
1
29
Mirena(R) removal from a nulliparous woman: response from Bayer HealthCare
Journal of Family Planning and Reproductive Health Care
2011
0
30
Abstract No. 196: Worldwide trends in locoregional therapy (LRT) for hepatocellular carcinoma (HCC): 2nd interim analysis (IA; 1500 patients [pts]) of the GIDEON (global investigation of therapeutic decisions in HCC and of its treatment with sorafenib) study
Journal of Vascular and Interventional Radiology
2012
0
31
Pharmaceutical Medicine in the Emerging Markets
Journal of Vascular and Interventional Radiology
2013
0
32
Global GIDEON data: Subgroup analysis of sorafenib dosing pattern in patients with unresectable hepatocellular carcinoma
Annals of Oncology
2016
0
33
Validation of REVEAL Risk Score Calculator 2.0 in Patients with PAH in the Phase III PATENT Study
Journal of Heart and Lung Transplantation
2020
0
34
Switching to Riociguat from Phosphodiesterase-5 Inhibitors, With or Without Endothelin Receptor Antagonists, in Patients with Pulmonary Arterial Hypertension: Results from the REPLACE Study
Journal of Heart and Lung Transplantation
2021
0
35
Safety of riociguat for the treatment of pulmonary hypertension: Data from the EXPERT registry
Journal of Heart and Lung Transplantation
2017
0
36
Effect of riociguat on pulmonary arterial compliance in patients with pulmonary arterial hypertension (PAH) in the RESPITE study
Journal of Heart and Lung Transplantation
2017
0
site/software ©
exaly
; All materials licenced under
CC by-SA
.